TY - JOUR
T1 - MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer
AU - Huo, Lei
AU - Wang, Yan
AU - Gong, Yun
AU - Krishnamurthy, Savitri
AU - Wang, Jing
AU - Diao, Lixia
AU - Liu, Chang-Gong
AU - Liu, Xiuping
AU - Lin, Feng
AU - Symmans, William F
AU - Wei, Wei
AU - Zhang, Xinna
AU - Sun, Li
AU - Alvarez, Ricardo H.
AU - Ueno, Naoto T
AU - Fouad, Tamer M.
AU - Harano, Kenichi
AU - Debeb, Bisrat Godefay
AU - Wu, Yun
AU - Reuben, James
AU - Cristofanilli, Massimo
AU - Zuo, Zhuang
N1 - Publisher Copyright:
© 2016 USCAP, Inc All rights reserved.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Inflammatory breast cancer is the most aggressive form of breast cancer. Identifying new biomarkers to be used as therapeutic targets is in urgent need. Messenger RNA expression profiling studies have indicated that inflammatory breast cancer is a transcriptionally heterogeneous disease, and specific molecular targets for inflammatory breast cancer have not been well established. We performed microRNA expression profiling in inflammatory breast cancer in comparison with locally advanced noninflammatory breast cancer in this study. Although many microRNAs were differentially expressed between normal breast tissue and tumor tissue, most of them did not show differential expression between inflammatory and noninflammatory tumor samples. However, by microarray analysis, quantitative reverse transcription PCR, and in situ hybridization, we showed that microRNA-205 expression was decreased not only in tumor compared with normal breast tissue, but also in inflammatory breast cancer compared with noninflammatory breast cancer. Lower expression of microRNA-205 correlated with worse distant metastasis-free survival and overall survival in our cohort. A small-scale immunohistochemistry analysis showed coexistence of decreased microRNA-205 expression and decreased E-cadherin expression in some ductal tumors. MicroRNA-205 may serve as a therapeutic target in advanced breast cancer including inflammatory breast cancer.
AB - Inflammatory breast cancer is the most aggressive form of breast cancer. Identifying new biomarkers to be used as therapeutic targets is in urgent need. Messenger RNA expression profiling studies have indicated that inflammatory breast cancer is a transcriptionally heterogeneous disease, and specific molecular targets for inflammatory breast cancer have not been well established. We performed microRNA expression profiling in inflammatory breast cancer in comparison with locally advanced noninflammatory breast cancer in this study. Although many microRNAs were differentially expressed between normal breast tissue and tumor tissue, most of them did not show differential expression between inflammatory and noninflammatory tumor samples. However, by microarray analysis, quantitative reverse transcription PCR, and in situ hybridization, we showed that microRNA-205 expression was decreased not only in tumor compared with normal breast tissue, but also in inflammatory breast cancer compared with noninflammatory breast cancer. Lower expression of microRNA-205 correlated with worse distant metastasis-free survival and overall survival in our cohort. A small-scale immunohistochemistry analysis showed coexistence of decreased microRNA-205 expression and decreased E-cadherin expression in some ductal tumors. MicroRNA-205 may serve as a therapeutic target in advanced breast cancer including inflammatory breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=84959236354&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959236354&partnerID=8YFLogxK
U2 - 10.1038/modpathol.2016.38
DO - 10.1038/modpathol.2016.38
M3 - Article
C2 - 26916073
AN - SCOPUS:84959236354
SN - 0893-3952
VL - 29
SP - 330
EP - 346
JO - Modern Pathology
JF - Modern Pathology
IS - 4
ER -